Treadwell Therapeutics, Inc

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 1 / Phase 2	2025-05-18		NCT05251714
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML	Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm	Active, not recruiting	Phase 1 / Phase 2	2025-05-18		NCT04730258

Clinical trials